Ipecacuanha: Difference between revisions

Jump to navigation Jump to search
m (Protected "Ipecacuanha": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
 
No edit summary
Line 1: Line 1:
{{Taxobox
{{DrugProjectFormSinglePage
| color = lightgreen
|authorTag=<!--Overview-->
| name = Ipecacuanha
|OTC=
| image = Koeh-251.jpg
|aOrAn=a
| image_width = 250px
|indicationType=
| regnum = [[Plant]]ae
|indication=
| divisio = [[Flowering plant|Magnoliophyta]]
|hasBlackBoxWarning=Yes
| classis = [[Magnoliopsida]]
|adverseReactions=<!--Black Box Warning-->
| ordo = [[Rubiales]]
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
| familia = [[Rubiaceae]]
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
| genus = ''[[Psychotria]]''
 
| species = '''''P. ipecacuanha'''''
* Content
| binomial = ''Psychotria ipecacuanha''
 
}}
<!--Adult Indications and Dosage-->
 
<!--FDA-Labeled Indications and Dosage (Adult)-->
|fdaLIADAdult======Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
* Dosing Information
 
:* Dosage
 
=====Condition3=====
 
* Dosing Information
 
:* Dosage
 
=====Condition4=====
 
* Dosing Information
 
:* Dosage
 
<!--Off-Label Use and Dosage (Adult)-->
 
<!--Guideline-Supported Use (Adult)-->
|offLabelAdultGuideSupport======Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Non–Guideline-Supported Use (Adult)-->
|offLabelAdultNoGuideSupport======Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Pediatric Indications and Dosage-->
 
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
|fdaLIADPed======Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Off-Label Use and Dosage (Pediatric)-->
 
<!--Guideline-Supported Use (Pediatric)-->
|offLabelPedGuideSupport======Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Non–Guideline-Supported Use (Pediatric)-->
|offLabelPedNoGuideSupport======Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Contraindications-->
|contraindications=* Condition1
 
<!--Warnings-->
|warnings=* Description
 
====Precautions====
 
* Description
 
<!--Adverse Reactions-->
 
<!--Clinical Trials Experience-->
|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
 
=====Cardiovascular=====
 
 
 
 
=====Digestive=====
 
 
 
 
=====Endocrine=====
 
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
 
=====Metabolic and Nutritional=====
 
 
 
 
=====Musculoskeletal=====
 
 
 
 
=====Neurologic=====
 
 
 
 
=====Respiratory=====
 
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
 
=====Special Senses=====
 
 
 
 
=====Urogenital=====
 
 
 
 
=====Miscellaneous=====
 
 
 
<!--Postmarketing Experience-->
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
=====Cardiovascular=====
 
 
 
=====Digestive=====
 
 
 
=====Endocrine=====
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
=====Metabolic and Nutritional=====
 
 
 
=====Musculoskeletal=====
 
 
 
=====Neurologic=====
 
 
 
=====Respiratory=====
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
=====Special Senses=====
 
 
 
=====Urogenital=====
 
 
 
=====Miscellaneous=====
 
 
 
<!--Drug Interactions-->
|drugInteractions=* Drug
:* Description
 
<!--Use in Specific Populations-->
|useInPregnancyFDA=* '''Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
 
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
|useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
|useInNursing=There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
|useInPed=There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
|useInGeri=There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
|useInGender=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
|useInRace=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
|useInRenalImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
|useInHepaticImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
|useInReproPotential=There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
|useInImmunocomp=There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
 
<!--Administration and Monitoring-->
|administration=* Oral
 
* Intravenous
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
 
* Description
 
<!--IV Compatibility-->
|IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
 
<!--Overdosage-->
|overdose====Acute Overdose===
 
====Signs and Symptoms====
 
* Description
 
====Management====
 
* Description
 
===Chronic Overdose===
 
There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacology-->
 
<!--Drug box 2-->
|drugBox=<!--Mechanism of Action-->
|mechAction=*
 
<!--Structure-->
|structure=*
 
: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
 
<!--Pharmacodynamics-->
|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacokinetics-->
|PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
 
<!--Nonclinical Toxicology-->
|nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
 
<!--Clinical Studies-->
|clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
 
<!--How Supplied-->
|howSupplied=*
|packLabel=<!--Patient Counseling Information-->
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
 
<!--Precautions with Alcohol-->
|alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
 
<!--Brand Names-->
|brandNames=* ®<ref>{{Cite web | title =  | url = }}</ref>


'''Ipecacuanha''' (''Psychotria ipecacuanha'') of family [[Rubiaceae]] is a [[flowering plant]], the root of which is most commonly used to make [[syrup of ipecac]], a powerful [[emetic]]. Its name comes from the [[Tupi language|Tupi]] ''i-pe-kaa-guéne'', translated as 'road-side sick-making plant'. It is native to [[Brazil]]. The plant had been assigned different names by various [[botany|botanists]]; several scientific names including ''Cephaelis acuminata'', ''Cephaelis ipecacuanha'', ''Psychotria ipecacuanha'', and ''Uragoga ipecacuanha'' were used.
<!--Look-Alike Drug Names-->
|lookAlike=* A® — B®<ref name="www.ismp.org">{{Cite web  | last =  | first =  | title = http://www.ismp.org | url = http://www.ismp.org | publisher =  | date =  }}</ref>


Ipecacuanha was first introduced to [[Europe]] in 1672, by a traveler named Legros. Legros imported some quantity of the root to [[Paris, France|Paris]] from [[South America]]. In 1680, a Parisian merchant named Garnier possessed some 68 kilograms (150 pounds) of the substance and informed a physician named [[Helvetius]] of its power in the treatment of [[dysentery]]. Helvetius was granted sole right to vend the remedy by [[Louis XIV of France|Louis XIV]], but sold the secret to the [[French government]], who made the [[formula]] public in 1688.
<!--Drug Shortage Status-->
|drugShortage=
}}
{{PillImage
|fileName=No image.jpg
}}
{{LabelImage
|fileName={{PAGENAME}}11.png
}}
{{LabelImage
|fileName={{PAGENAME}}11.png
}}
<!--Pill Image-->


The part of ipecacuanha used in medicine is the root, which is simple or divided into a few branches, flexuous, about as thick as a goose [[quill]], and is composed of rings of various size, somewhat fleshy when fresh, and appearing as if closely strung on a central woody cord.  The different kinds known in commerce (gray, red, brown) are all produced by the same plant, the differences arising from the age of the plant, the mode of drying, etc. Various other plants are used as substitutes for it.


Ipecacuanha is useful as an [[emetic]] when it is necessary to unload the stomach in cases where there is great debility or in childhood. As a [[nauseant]], [[expectorant]], and [[diaphoretic]], it is prescribed in [[bronchitis]], etc., and in disorders in which it is desired to increase the actions of the skin. The most useful preparations are the [[syrup of ipecac|wine of ipecacuanha]] and [[Dover's powder]].


==Similar plants==
<!--Label Display Image-->
Ipecacuanha is a slow-growing plant, which reduces its commercial appeal as a crop plant. It is seldom cultivated in [[South America]], but it has been cultivated in [[India]] and elsewhere. 


Botanical naming practices vary and change a great deal, thus the following is a generalized listing of plants which have at some point in time been employed as substitutes for ipecacuanha.  Some of the names of the species may be obsolete.


*Brazilian or Rio ipecacuanha: ''Cephaelis ipecacuanha''{{Verify source|date=September 2007}}
*Cartagena or Colombia ipecacuanha: ''Cephaelis acuminata''{{Verify source|date=September 2007}}
*Wild ipecacuanha: ''Euphorbia ipecacuanhae'' of [[North America]]
*[[Venezuela|Venezuelan]] plant: ''Sarcostemma glacum'', of the family [[Asclepiadaceae]]
*''Tylophora asthmatica'' was used in [[India]]
*''Gillenia stipulata'' was called American ipecac
*''Richardsonia pilosa, Richardsonia rosea, Psychotria emetica'' and various species of ''Ionidium'' have been employed, too.


==Other==
*Ipecacuanha was the name of the ship that initially rescued the character Edward Prendick in the novel ''[[The Island of Doctor Moreau]]'' written by [[H. G. Wells]]. The ship he had been on, the Lady Vain, collided with rocks, and he was left to float in a dingy until he was rescued eight days later.
*[[Guybrush Threepwood]] used Ipecacuanha syrup (made by combining a flower from the Ipecacuanha with maple syrup) in order to escape from the giant snake that swallowed him in ''[[The Curse of Monkey Island|Monkey Island 3: The Curse of Monkey Island]]'' [[videogame]].


==External links==
;Therapeutic classification
*{{ATC|R05|CA04}}


{{Cough and cold preparations}}
<!--Category-->
{{Antidotes}}
[[Category:Rubiaceae]]
[[Category:Flora of Brazil]]
[[Category:Medicinal plants]]


[[de:Brechwurzel]]
[[Category:Drug]]
[[es:Psychotria ipecacuanha]]
[[fr:Ipécacuanha]]
[[ms:Pokok Ipecacuanha]]
[[ja:トコン]]
[[pl:Ipekakuana prawdziwa]]
[[pt:Ipecacuanha]]
[[sv:Kräkrot]]
{{WikiDoc Sources}}

Revision as of 20:15, 16 February 2015

Ipecacuanha
Black Box Warning
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Black Box Warning

ConditionName:
See full prescribing information for complete Boxed Warning.
ConditionName:
  • Content

Overview

Ipecacuanha is a {{{drugClass}}} that is FDA approved for the of . There is a Black Box Warning for this drug as shown here. Common adverse reactions include .

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Condition1
  • Dosing Information
  • Dosage
Condition2
  • Dosing Information
  • Dosage
Condition3
  • Dosing Information
  • Dosage
Condition4
  • Dosing Information
  • Dosage

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Ipecacuanha in adult patients.

Non–Guideline-Supported Use

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Ipecacuanha in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding FDA-Labeled Use of Ipecacuanha in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Ipecacuanha in pediatric patients.

Non–Guideline-Supported Use

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Ipecacuanha in pediatric patients.

Contraindications

  • Condition1

Warnings

ConditionName:
See full prescribing information for complete Boxed Warning.
ConditionName:
  • Content
  • Description

Precautions

  • Description

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Ipecacuanha in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Ipecacuanha in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Drug Interactions

  • Drug
  • Description

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Pregnancy Category


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Ipecacuanha in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Ipecacuanha during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Ipecacuanha with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Ipecacuanha with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Ipecacuanha with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Ipecacuanha with respect to specific gender populations.

Race

There is no FDA guidance on the use of Ipecacuanha with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Ipecacuanha in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Ipecacuanha in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Ipecacuanha in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Ipecacuanha in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Oral
  • Intravenous

Monitoring

There is limited information regarding Monitoring of Ipecacuanha in the drug label.

  • Description

IV Compatibility

There is limited information regarding IV Compatibility of Ipecacuanha in the drug label.

Overdosage

Acute Overdose

Signs and Symptoms

  • Description

Management

  • Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Ipecacuanha in the drug label.

Pharmacology

There is limited information regarding Ipecacuanha Pharmacology in the drug label.

Mechanism of Action

Structure

File:Ipecacuanha01.png
This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Ipecacuanha in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Ipecacuanha in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Ipecacuanha in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Ipecacuanha in the drug label.

How Supplied

Storage

There is limited information regarding Ipecacuanha Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Ipecacuanha |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Ipecacuanha |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Ipecacuanha in the drug label.

Precautions with Alcohol

  • Alcohol-Ipecacuanha interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Look-Alike Drug Names

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. Empty citation (help)
  2. "http://www.ismp.org". External link in |title= (help)

{{#subobject:

 |Page Name=Ipecacuanha
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject:

 |Label Page=Ipecacuanha
 |Label Name=Ipecacuanha11.png

}}

{{#subobject:

 |Label Page=Ipecacuanha
 |Label Name=Ipecacuanha11.png

}}